Author

Ferdinando D'Amico

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

Ferdinando D'Amico  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

Ferdinando D'Amico  et al.

Item 1 - 2 / 2
1